Reduced hyaluronan cross-linking induces breast cancer malignancy in a CAF-dependent manner

Guoliang Zhang¹², Yiqing He¹, Yiwen Liu¹, Yan Du¹, Cuixia Yang¹² and Feng Gao¹²

Abstract

Hyaluronan (HA) cross-linking is a conformational state of HA, a covalent complex between HA and heavy chains (HCs) from inter-α-trypsin inhibitor (I-α-I) mediated by tumor necrosis factor-induced protein 6 (TSG6). Cross-linked HA has been identified as a protective factor in physiological and inflammatory conditions. However, the state of HA cross-linking in tumor microenvironment has not been fully elucidated. As a major constituent of the extracellular matrix (ECM), HA is mainly synthesized by cancer-associated fibroblasts (CAFs). Our study aimed to clarify the role of HA cross-linking in breast cancer malignancy. Compared to normal mammary gland tissues, cross-linked HA levels were significantly decreased in breast cancer and associated with tumor malignancy. When NFbs were activated into CAFs, the levels of cross-linked HA and TSG6 were both suppressed. Through upregulating TSG6, CAFs restored the high level of cross-linked HA and significantly inhibited breast cancer malignancy, whereas NFbs promoted the malignancy when the cross-linked HA level was reduced. Furthermore, the inhibitory role of HA cross-linking in tumor malignancy was directly verified using the synthesized HA-HC complex. Collectively, our study found that the deficiency of cross-linked HA induced breast cancer malignancy in a CAF-dependent manner, suggesting that recovering HA cross-linking may be a potential therapeutic strategy.

Introduction

During malignancy, tumor cells must establish a favorable microenvironment or niche that will sustain their growth. Cancer-associated fibroblasts (CAFs) are the most abundant mesenchymal cells in the tumor microenvironment¹. CAFs not only promote tumor malignancy but also serve as a marker for cancer diagnosis, treatment, and prognosis²–⁴. When normal fibroblasts (NFbs) are activated into CAFs, the cytokines secreted and extracellular matrix (ECM) around were altered dramatically⁵. The pathological remodeling of ECM affects the proliferation, survival, and metastasis of tumor cells⁶,⁷. Hyaluronan (HA), a linear polysaccharide composed of repeating disaccharide units of D-glucuronic acid and N-acetyl-d-glucosamine⁸, is the major constituent of ECM. HA is synthesized by three kinds of HA synthases on the plasma membrane and can be secreted into the surrounding microenvironment. Under physiological conditions, HA is immunologically quiescent and can maintain cell stability. In the tumor microenvironment, the synthesis and degradation of HA both increase, resulting in the abnormal accumulation of HA fragments. Most current studies focus on the role of HA with different molecular weights (MWs) in tumor malignancy⁹. For example, low MW HA (LMW-HA) has been reported to possess many pro-tumor activities that are not exerted by high MW HA (HMW-HA). Studies on naked mole rats have found that ultra-high MW HA has an antitumor effect¹⁰. Through binding to receptors, such as CD44, lymphatic vessel endothelial receptor 1, and receptor for HA-mediated motility, LMW-HA can induce angiogenesis and lymphangiogenesis, accelerate cancer cell migration, and contribute to the expression of matrix metalloproteinases¹¹–¹⁴. However, whether there is a
conformational change of HA in tumor microenvironment has not been well described.

Actually, the HA matrix can be modified by dynamic patterns of hyaladherins, which can change the conformation of HA and expand the repertoire of HA interactions with ECM components. One of the best examples of HA conformational changes is cross-linking. HA cross-linking has been well characterized as the covalent complex formed between HA and heavy chains (HCs) from inter-α-trypsin inhibitor (I-α-I), which is induced by tumor necrosis factor-induced protein 6 (TSG6)\textsuperscript{15–17}. TSG-6 can also mediate the cross-linking of HA itself but is impaired in the presence of I-α-I\textsuperscript{18}. In TSG6-deficient mice, the formation of covalent complexes between HA and HCs was impaired, making cumulus cells unable to assemble HA-rich ECM, resulting in female mice infertility\textsuperscript{19}. HA cross-linking was also found in inflammatory diseases\textsuperscript{20,21}. The cross-linked HA in synovial fluid can increase its viscosity, reduce HA loss, and resist the adverse effects of HA-degraded fragments in arthritis\textsuperscript{21}. In addition, the cross-linked HA can be used as a “water tank” for oxygen radicals to inhibit inflammation\textsuperscript{22}. The above studies show that cross-linked HA can maintain normal fertility and has anti-inflammatory effects. However, the state of HA cross-linking in cancer progression, particularly in tumor microenvironment, is unknown. Given the protective role of cross-linked HA in physiological and inflammatory processes, we propose that HA cross-linking might become deficient during tumor malignancy.

It is well known that HA levels are usually increased in many solid tumors, such as colorectal, prostate, and breast cancer\textsuperscript{23–25}. A clinical survey has proved a close correlation between high-stromal HA enrichment and poor survival in breast cancer patients\textsuperscript{26,27}. In tumor microenvironment, CAFs are a major source of ECM in “cancerized” stroma that impact tumor initiation and progression. Suppressing the HA synthesis in CAFs can inhibit the malignancy of several solid cancers\textsuperscript{28–31}. Therefore, CAFs are critical for studying the role of HA cross-linking in breast cancer malignancy.

In this study, the state of HA cross-linking was first clarified in the breast cancer microenvironment. Next, the change of cross-linked HA levels was observed when NFbs were activated into CAFs. Then the effects of HA cross-linking on tumor malignancy were determined by co-culturing tumor cells with NFbs or CAFs with different levels of cross-linked HA, as well as using the synthesized cross-linked HA. We found that HA cross-linking was deficient in the breast cancer microenvironment due to TSG6 downregulation in CAFs. When cross-linked HA was restored in CAFs, the breast cancer malignancy was significantly suppressed.

**Materials and methods**

**Patients**

Patients diagnosed with breast cancer ($n = 16$) were enrolled. Patients who received chemotherapy or radiotherapy before surgery were excluded. Details concerning clinical characteristics are provided in Table S1. Tumors were staged according to the tumor–node–metastasis staging system\textsuperscript{32}.

**Mouse model and cell culture**

The MMTV-PyMT (polyomavirus middle T antigen) mouse model was applied for the widely accepted reason that it can mimic several aspects of human breast cancer, including initiation, histological and molecular progression, metastasis, and immunotherapies. Despite not being a human oncogene, PyMT imitates the signaling of receptor tyrosine kinases, which are commonly activated in human breast cancer\textsuperscript{33}.

Primary MMTV tumor cells were isolated from breast cancer tissues of 12–14-week MMTV-PyMT mice. The tumors were isolated and cut into small pieces. After digestion using a mouse tumor disassociation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s instructions, single cells were obtained. Tumor cells were defined as CD45$^-$ /EpCAM$^+$ cells and purified by a fluorescence-activated cell sorting instrument. NFbs from mammary glands of FVB mice and CAFs from breast cancer tissues of MMTV-PyMT mice were isolated as previously reported\textsuperscript{34}. All NFbs and CAFs were used for experiments at P1–P5. Different kinds of fibroblasts were cultured in Dulbecco’s modified Eagle’s medium/F12 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin (100×), 5 μg/ml insulin, 5 ng/ml basic fibroblast growth factor, 1 μg/ml hydrocortisone, and 50 μg/ml ascorbic acid.

**Immunohistochemistry and immunofluorescence**

Tissues from patients or mice were fixed, embedded in paraffin, and cut at 5 μm thickness. The sections were dewaxed, hydrated, processed with antigen retrieval and inhibition of endogenous peroxidase, and blocked. For immunohistochemistry, the sections were covered with anti-Ki67 antibody (1:800, Abcam, Cambridge, MA, USA) and incubated overnight at 4 °C. Then the sections were immersed with secondary antibody, followed by streptavidin-ABC, developed with DAB solution, and counterstained using hematoxylin. For immunofluorescence, the sections were first incubated with anti-vimentin (1:500, Abcam), anti-TSG6 (1:100, R&D, Minneapolis, MN, USA), anti-HC1(1:200, Invitrogen, Carlsbad, CA, USA), or anti-HC2 (1:200, Invitrogen) antibodies overnight at 4 °C. Then the sections were immersed with corresponding fluorescent secondary antibodies labeled with Alexa Fluor 488 for 1 h at room temperature. After incubation with
biotinylated hyaluronate-binding protein (HABP, 5 μg/ml, Merck, Darmstadt, Germany) overnight at 4 °C, the sections were immersed with Alexa Fluor® 647-conjugated streptavidin (1:800, Yeasen Biotech, Shanghai, China). Finally, the slides were mounted using an antifade mounting medium with 4,6-diamidino-2-phenylindole (DAPI; Abcam) and photographed with a confocal microscope (Nikon, Japan).

For Ki67 staining, MMTV tumor cells were fixed by 4% paraformaldehyde. After permeabilization and blocking, cells were incubated with anti-Ki67 antibody (1:800, Abcam) overnight at 4 °C. Alexa Fluor® 594-conjugated secondary antibody (1:800, Abcam) was applied and DAPI was used to stain nuclei. For HA staining, NFbs and CAFs were seeded in 24-well cell culture plate with a glass bottom (6 × 104 cells per well) and cultured for 48 h. Cells were fixed with AAF fixative (95% ethyl alcohol 34 ml + glacial acetic acid 2 ml + formalin 4 ml) at −20 °C for 20 min. After blocking and incubation with HABP (5 μg/ml) overnight at 4 °C, Alexa Fluor® 488-conjugated streptavidin was applied at 1:800. Cells were observed under a confocal microscope after staining with DAPI.

Lentiviral infection
Lenti-shTSG6 (mouse) and control viruses were obtained from Santa Cruz (Dallas, TX, USA). Lenti-TSG6 (mouse) and control viruses were acquired from GeneCopoeia (Rockville, MD, USA). Lenti-shTSG6 and corresponding viruses were transfected into NFbs with polybrene (5 μg/ml), whereas Lenti-TSG6 and control viruses were transfected into CAFs. After 24 h, the cells were selected using puromycin for another 48 h and used for different kinds of experiments.

Western blot
Cells were washed with cold phosphate-buffered saline (PBS) and lysed in RIPA lysis buffer. Then proteins were separated via sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10%) gels and transferred to polyvinylidene difluoride membranes. The membranes were incubated with blocking buffer, followed by primary antibodies against vimentin (1:1000, Abcam), alpha-smooth muscle actin (α-SMA; 1:1000, Sigma, St. Louis, USA), TSG6 (1:100, R&D), I-α-1 (1:1000, Dako, Carpinteria, CA, USA), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:1000, CST) as well as horseradish peroxidase (HRP)-labeled secondary antibodies. ECL method was used to detect the specific bands.

Real-time PCR
Total RNA was isolated from NFbs and CAFs using TRIzol reagent (Takara, Japan). After quantification using a NanoDrop 2000 spectrophotometer, purified total RNA was reverse-transcribed, and quantitative real-time PCR was conducted by an ABI 7500 instrument with SYBR Premix Ex Taq™ (Takara) according to the manufacturer’s instructions. The primers used were mouse TSG6, 5′-GATAACAGCTCACCTACGCGAAG-3′ (forward) and 5′-GCCATCCATCCAGCAGACAG-3′ (reverse); and GAPDH, 5′-CATCAG CGCCAACCAGAGACTG-3′ (forward) and 5′-ATGCCAGTGAGCTTCCCGT TCAG-3′ (reverse).

Tumor–stromal assay (TSA)
In TSA, 12-well cell culture plates with a glass bottom and press-to-seal silicon isolators with round wells (2 mm diameter, Sigma) were used. The culture plate was coated with collagen overnight, and isolators were put into glass wells. After staining with a cell tracker, MMTV tumor cells were seeded into the round wells of isolators (3000 cells per well) and incubated for 1 h. After incubation overnight in 1 ml complete medium, isolators were removed. Then 5 × 104 fibroblasts were seeded and incubated for 30 min. The wells were washed to remove the fibroblasts that landed on the tumor cell islands. After 72 h, Ki67 was stained.

Apopotosis assay
The apoptosis was determined using TACS® 2TdT-DAB Apoptosis Detection Kit (Trevigen, Gaithersburg, USA) as per the manufacturer’s instruction. MMTV tumor cells were seeded into 96-well plates and stimulated with or without 50% conditioned media (CM) from different fibroblasts for 72 h. Samples were fixed by 4% paraformaldehyde and covered with 50 μl of Cytonin™ for 30 min. After immersing in quenching solution for 5 min and washing by PBS, samples were incubated in labeling buffer for 5 min. Next, samples were covered with 50 μl of labeling reaction mix and incubated for 60 min at 37 °C. After stopped by the TdT stop buffer, samples were covered with 50 μl of Strep-HP solution for 10 min at 37 °C. Then samples were incubated in DAB solution for 3 min and counterstained by 1% methyl green for 1 min. For the quantification of apoptotic cells, five randomly selected fields (×400 magnification) were counted.

Colony formation assay
MMTV tumor cells were seeded at 1000 cells per well in the 12-well culture plates and stimulated with 50% CM of different fibroblasts. After incubation at 37 °C for 10 days, cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet solution.

Migration and invasion assay
The migration and invasion were conducted using 8 μm transwell chambers (Corning, Cambridge, USA) and 8 μm matrigel invasion chambers (BD Biosciences), respectively. In all, 5 × 104 tumor cells were seeded for migration
and $1 \times 10^5$ cells for invasion. The upper chambers were filled with 250 μl serum-free medium or 100% CM from fibroblasts, whereas the lower chambers were filled with 500 μl medium supplemented with 10% FBS. After 24 h, invaded cells were stained with crystal violet and quantified under a microscope by counting them in five random fields ($\times 100$ magnification).

For the direct co-culture, $5 \times 10^4$ tumor cells pre-stained with cell tracker (green, Invitrogen) were mixed with or without different fibroblasts ($5 \times 10^4$) and seeded in the upper chambers of migration or invasion assay. After incubation for 24 h, cells invading into the bottom surface of the inserts were observed under a fluorescence microscope.

**HA electrophoresis**

CM of fibroblasts was concentrated and digested at 50°C overnight using proteinase K (Sigma). After the proteinase K was inhibited by pefabloc SC (Sigma), benzonase endonuclease (Sigma) was added to remove nucleic acid. Total polysaccharides were extracted using phenol/chloroform extraction followed by EtOH precipitation. Finally, a corresponding volume of 10 mM Tris-HCl (pH 8.5) was added to dissolve the pellet. The size distribution of HA was analyzed by agarose gel electrophoresis. The HA samples were loaded on a 0.8% agarose gel and electrophoresed. The gel was stained with 0.005% Stains-All (Sigma) overnight in the dark. Then the gel was placed in distilled H2O under ambient light to destain and photographed.

**HA-HC complex synthesis**

HA-HC complex was synthesized as reported before. HA (H5388, Sigma), recombinant mouse TSG-6 protein (R&D), and mouse serum (isolated from female FVB mouse) were used. The reaction volume of HA-HCa was 250 μl, containing 50 μl HA (2 mg/ml, Sigma), 100 μl mouse serum, 80 μl TSG6 (5 μg/ml, R&D), and 20 μl PBS. The volumes were altered correspondingly in the groups of HA, HA $+$ I-α-I, and HA-HCb. The mixtures were incubated at 37°C for 24 h and stopped by adding 5 μl EDTA solution (0.5 M, pH 8.0). After the reaction, the products were incubated with or without 20 units/ml hyaluronidase at 37°C for 1 h. Then the samples were combined with loading buffer and boiled to denaturation. Western blot was used to confirm the existence of HA-HC complex. After dilution (1:8) with culture media, HA-HC complex was used to stimulate MMTV tumor cells.

**Animal experiment**

Female athymic BALB/c nude mice (5–6 weeks old) were used for animal studies. MMTV tumor cells ($1 \times 10^5$) alone or admixed with different fibroblasts ($3 \times 10^5$) were orthotopically injected into the mammary fat pads of mice ($n = 5$ per group). Cells were resuspended in cold 50% Growth Factor Reduced Matrigel (BD Biosciences) before injection. Mice were randomly allocated to different experimental groups and processed. The investigator was not blinded to the group allocation during the experiment. Tumors were measured with calipers every 3–4 days, and volumes were calculated using the formula “width$^2 \times$ length $\times 0.52$.” Mice were sacrificed when the tumor diameter exceeded 1 cm. Then samples were isolated, photographed, fixed, and embedded by paraffin for immunohistochemistry and immunofluorescence.

**Statistical analysis**

Statistical analyses between two groups were performed using Student’s $t$ test or Mann–Whitney rank-sum test (where appropriate). The variance between the groups that are being statistically compared is similar. SPSS 19.0 statistical software (SPSS, San Diego, CA, USA) was used to analyze our data. In all cases, $p < 0.05$ was considered to be significant.

**Results**

**HA cross-linking was decreased in breast cancer tissues and associated with tumor stage**

HCs of I-α-I can be transferred to HA, forming the HA-HC complex, which is called the cross-linked HA. Therefore, the co-localization of HA and I-α-I HCs is usually used to determine the existence of HA cross-linking in tissues. In our study, HA and I-α-I HCs were simultaneously stained using immunofluorescence to verify the expression of cross-linked HA in tissues from breast cancer patients. In normal breast tissues, HA was co-localized with I-α-I HC1 or I-α-I HC2, suggesting that HA was covalently modified with HCs of I-α-I to form HA-HC complexes. In contrast, both HA-HC1 and HA-HC2 complexes were significantly decreased in cancer tissues from patients with stage I breast cancer and were almost disappeared in stage III breast cancer (Fig. 1).

We also confirm the result using normal mammary gland tissues from wild-type (FVB) mice and cancer tissues from MMTV-PyMT mice with early (week 10) or late (week 16) stage breast cancer. As shown by immunofluorescence, the levels of HA-HC1 and HA-HC2 complexes were markedly decreased in breast cancer tissues from MMTV-PyMT mice and negatively associated with breast cancer stages (Fig. 1). Moreover, immunoblotting was used to further clarify the difference of HA-HC complex in mouse normal and breast cancer tissues. As shown in Fig. S1A, the level of HA-HC complex was extensively decreased in cancer tissues.

**CAFs were responsible for HA cross-linking deficiency in breast cancer**

To clarify which kind of cells are responsible for the deficiency of HA cross-linking in breast cancer, we
simultaneously determined the expression of HA and vimentin using immunofluorescence. As shown in Fig. 2A and Fig. S1B, the distribution pattern of HA was the same as vimentin, suggesting that CAFs are the main source of HA. Then we isolated NFbs and CAFs from mammary glands of FVB mice and breast cancer tissues of MMTV-PyMT mice, respectively. NFbs and CAFs were both positive for vimentin, whereas α-SMA was only significantly increased in CAFs (Fig. 2C), indicating that NFbs and CAFs were successfully isolated and cultured. Importantly, we found that HA could form cable-like structures in NFbs, which was the cross-linked HA. However, the cross-linked HA was deficient in

---

**Fig. 1 HA cross-linking was decreased in breast cancer tissues and associated with tumor stage.**

A. Immunofluorescence staining of HA (red) and I-α-I HC1 (green) in cancer tissues and corresponding adjacent normal tissues from patients with early (stage I, n = 7) or late (stage III, n = 9) staged breast cancer, normal mammary gland tissues from FVB mice, and cancer tissues from MMTV-PyMT mice with early (week 10) or late (week 16) staged breast cancer. B. Immunofluorescence staining of HA (red) and I-α-I HCs (green) in corresponding tissues. The white arrowheads refer to the co-localization of HA and I-α-I, which means HA cross-linking. HA and I-α-I HCs were both localized within and outside of cells. C. The intensity ratio of HA co-localized with I-α-I HCs to total HA was used to determine the levels of HA-HC complexes. The intensity percentage of HA-HCs co-localization was acquired by the Image J software. Error bars show mean ± SD values. Statistical analysis was performed using Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
CAFs (Fig. 2B). Furthermore, NFbs and CAFs were isolated and cultured from surgical specimens of breast cancer patients. As shown in Fig. S2A, HA cross-linking was also disappeared in CAFs.

TSG6 has been implicated as a critical regulator of HA cross-linking in inflammatory diseases and can be expressed in macrophages stimulated with lipopolysaccharide. Next, we determine whether TSG6 contributes to the deficiency of
cross-linked HA in breast cancer. In early-staged breast cancer tissues, TSG6 was mainly derived from CAFs, not macrophages (Fig. S3). The level of TSG6 was significantly decreased in late-staged breast cancer tissues (Fig. 2D). Moreover, TSG6 was also considerably downregulated in CAFs (Fig. 2E). Then we validated the role of TSG6 in mediating HA cross-linking. When TSG6 was downregulated, the cross-linked HA was markedly reduced in NFbs (Fig. 2F and Fig. S4A). Our rescue experiment indicated that only wild-type TSG6 could restore the HA cross-linking in NFbTSG6−, whereas catalytically inactive TSG6 (S28A)38 had no effect (Fig. S4B). Meanwhile, the cross-linked HA was significantly increased in CAFs after restoring TSG6 expression (Fig. 2F).

**Disorganization of HA cross-linking in NFbs promoted breast cancer malignancy**

To explore the role of HA cross-linking in tumor malignancy, we altered the expression of cross-linked HA in fibroblasts by regulating TSG6. First, we downregulated TSG6 expression in NFbs derived from normal mammary glands of FVB mice. NFbControl and NFbTSG6− with different levels of cross-linked HA were separately co-cultured with MMTV tumor cells. The TSA was used to simulate the interaction between tumor cells and stromal fibroblasts. As shown in Fig. S5A and Fig. 3A, the tumor cell islands were surrounded by fibroblasts. In TSA, the Ki67-positive rate of tumor cells was suppressed by NFbControl cells, whereas NFbTSG6− cells with reduced cross-linked HA significantly promoted the proliferation (Fig. 3A, D). Meanwhile, the apoptotic rate of tumor cells treated with 50% CM of NFbControl cells was higher than with tumor cells alone but was significantly decreased when stimulated by NFbTSG6− CM (Fig. 3B, D). Besides, NFbTSG6− CM markedly accelerated the colony formation ability (Fig. 3C, D). For migration and invasion, NFbTSG6− CM with a reduced level of cross-linked HA had a promoting effect on tumor cells compared to NFbControl CM (Fig. 3E). A similar result was obtained when tumor cells stained with a cell tracker were directly co-cultured with NFbControl or NFbTSG6− cells (Fig. S4B).

**The ability of CAFs in promoting breast cancer was inhibited when HA cross-linking was reacquired**

Next, we tried to verify whether CAFs would affect breast cancer malignancy when HA cross-linking was restored. After overexpression of TSG6, the level of cross-linked HA in CAFs derived from breast cancer tissues of MMTV-PyMT mice can be significantly increased (Fig. 2F). Then CAFTSG6+ and CAFTSG6− cells were separately co-cultured with tumor cells. As shown in Fig. 4A, D, the Ki67-positive rate in TSA was significantly higher in tumor cells co-cultured with CAFTSG6+ cells. However, CAFTSG6+ cells with a high level of cross-linked HA markedly suppressed the proliferation. In the apoptosis assay, CAFTSG6− CM significantly inhibited the apoptotic rate, which was not observed in CAFTSG6+ CM (Fig. 4B, D). Besides, the acceleration of CAFTSG6+ CM to the colony formation of tumor cells was substantially decreased (Fig. 4C, D). When MMTV tumor cells were stimulated with 50% CAF CM or directly co-cultured with CAFs, the migration and invasion abilities were inhibited by CAFTSG6+ cells (Fig. 4E and Fig. S5C).

To explore the possible effect of TSG6 on the MW of HA in fibroblasts, HA derived from NFbControl, NFbTSG6−, CAFControl, and CAFTSG6+ cells was analyzed using electrophoresis. As shown in Fig. S6A, TSG6 did not alter the MW of HA significantly. In addition, TSG6 had no significant effect on the levels of pro-tumor cytokines transforming growth factor (TGF)-β, interleukin (IL)-6, epidermal growth factor (EGF), and hepatocyte growth factor (HGF) secreted by CAFs (Fig. S6B).

**Cross-linked HA constructed in vitro suppressed breast cancer malignancy**

The above results have shown that the different levels of cross-linked HA in fibroblasts can significantly affect the malignancy of breast cancer. To further identify the role of HA cross-linking alone, we next synthesized cross-linked HA (HA-HC complex) in vitro using HMW-HA and evaluated its effects on MMTV tumor cells. The cross-linked HA was confirmed by western blot (Fig. S7). As shown in Fig. 5A, HA-HCa significantly suppressed the Ki67-positive rate and promoted the apoptosis of tumor cells, whereas HA, HA + I-α-I, and HA + TSG6 had no significant effect. Considering the critical role of TSG6 in the formation of HA-HC complex, the concentration of TSG6 in HA-HCb was reduced to half of that used in HA-HCa, which means that the quantity of HA-HC complex in HA-HCb was significantly reduced. As expected, the inhibitory effects on MMTV tumor cells were markedly relieved in the HA-HCb group (Fig. 5A), suggesting that the impact of HA-HC complex was concentration dependent. For migration and invasion, a similar result was observed (Fig. 5B).

Moreover, to determine whether LMW-HA enriched in tumor microenvironment could have cross-linking activity, different kinds of LMW-HA were used to synthesize cross-linked LMW-HA. The result showed that only 200 kDa HA could form the HA-HC complex (Fig. S8A). As shown in Fig. S8B, C, LMW-HA promoted the proliferative and invasive abilities of tumor cells, whereas the pro-tumor effects were not observed in cross-linked LMW-HA, further confirming the suppressive role of HA-HC complex in tumor malignancy.

**HA cross-linking deficiency promoted breast cancer malignancy in vivo**

The inhibitory role of HA cross-linking in the process of breast cancer malignancy has been verified in vitro.
Next, MMTV tumor cells alone or mixed with NFbControl, NFbTSG6−, CAFControl, and CAFTSG6+ cells were orthotopically injected into mammary fat pads of female nude mice to observe the tumor growth and invasion. As shown in Fig. 6A, CAFControl cells could significantly promote tumor growth, whereas the growth was markedly suppressed by NFbControl cells. In contrast to the NFbControl group, the NFbTSG6− group had much larger tumor volumes. Meanwhile, the tumor volumes in the CAFTSG6+ group were significantly smaller than those in the CAFControl group. A similar result was also found in tumor weights (Fig. 6B). As shown in Fig. 6C, the Ki67-positive rates in the NFbControl

Fig. 3 Disorganization of HA cross-linking in normal fibroblasts promoted breast cancer malignancy. A Primary tumor cells from MMTV-PyMT mice were stained with cell tracker (green) and then co-cultured with or without corresponding normal fibroblasts (NFbControl and NFbTSG6−) in the tumor–stromal assay (TSA). As shown in the left image, tumor cells (green) were in the middle of TSA and surrounded by fibroblasts (red, illustrated by staining vimentin). After 72 h, the proliferation of tumor cells was determined by staining Ki67. The top panel shows the representative images of tumor cells (green) with nuclei (DAPI). The down panel shows the Ki67 expression (red) in corresponding nuclei. B After stimulation with 50% conditioned media (CM) of NFbControl or NFbTSG6−, the apoptosis of tumor cells was evaluated by the TdT-DAB apoptosis assay. Red arrows indicate the apoptotic tumor cells. C The colony formation abilities of tumor cells treated with NFbControl CM or NFbTSG6− CM. D The statistical histograms of Ki67 percentage, apoptotic percentage, and colony count of tumor cells in different groups. E The migration and invasion abilities of tumor cells. All experiments were repeated three times with similar results. Error bars represent mean ± SD values. Statistical analysis was performed using Student’s t test. **p < 0.01, ***p < 0.001 (vs NFbControl or NFbControl CM), ##p < 0.01 (vs Control).
and CAF_{TSG6+} groups were significantly lower than that in the NFb_{TSG6−} and CAF_{Control} groups, respectively. Besides, we found that MMTV tumor cells in the NFb_{TSG6−} and CAF_{Control} groups were much easier to invade the muscle tissues than those in the NFb_{Control} and CAF_{TSG6+} groups (Fig. 6D).

We further verified whether the differences of tumor malignancy between groups are primarily due to HA cross-linking. As shown in Fig. 7A, HA was mainly distributed in stoma and co-localized with fibroblasts (vimentin^+) in all the groups. The levels of TSG6 in NFb_{Control} and CAF_{TSG6+} groups were much higher compared to the NFb_{TSG6−} and CAF_{Control} groups, respectively (Fig. 7B). As expected, cancer tissues in the NFb_{Control} and CAF_{TSG6+} groups had more HA-HC1 and HA-HC2 complexes than that in the NFb_{TSG6−} and CAF_{Control} groups (Fig. 7C–E).

As shown in Fig. 7F, when NFbs are activated into CAFs, TSG6 is downregulated. Meanwhile, the levels of cross-linked HA are dramatically decreased, followed by an increment of tumor malignancy.

**Discussion**

The promoting role of HA in breast cancer malignancy has been well characterized. Previous studies mainly focused on the quantity and MW of HA in the tumor microenvironment. In this study, we investigated the role of HA in tumor malignancy from a novel perspective, the change of conformation. In the breast cancer microenvironment, we found that cross-linked HA levels were
significantly reduced in a CAF-dependent manner, together with an accelerating effect on tumor cell proliferation, migration, and invasion.

HA cross-linking has been identified in physiological and inflammatory conditions and is critical for reproduction and anti-inflammation\(^{19,39,40}\). Our study illustrated that cross-linked HA levels were significantly decreased in breast cancer tissues and negatively associated with tumor malignancy. Therefore, we proposed that HA cross-linking might have an inhibitory role in the process of breast cancer.

**Fig. 5** HA cross-linking constructed in vitro suppressed breast cancer malignancy. **A** After treatment with HA, HA + TSG6, HA + I-\(\alpha\)-I, HA-HCa (HA + I-\(\alpha\)-I + TSG6), or HA-HCb (HA + I-\(\alpha\)-I + 1/2 concentrated TSG6), the proliferation and apoptosis of MMTV tumor cells were determined. Red nuclei refer to the Ki67-positive ones, and red arrowheads refer to the apoptotic tumor cells. **B** The migration and invasion abilities of tumor cells in different groups. All experiments were repeated three times with similar results. Error bars represent mean ± SD values. Statistical analysis was performed using Student’s t test. ***p < 0.001 (vs Control), **p < 0.01, ###p < 0.001 (vs HA-HCa).
In many solid tumors, HA was mainly distributed in the stroma and synthesized by CAFs\textsuperscript{29–31}. In breast cancer tissues from patients and MMTV-PyMT mice, our data also demonstrated that CAFs were mainly responsible for HA accumulation in cancer stroma. Therefore, we isolated and cultured NFbs and CAFs from mice and breast cancer patients. As expected, the HA level in CAFs was significantly higher than that in NFbs, which is in line with previous studies showing that fibroblasts synthesize more HA when activated into CAFs\textsuperscript{41}. However, the cross-linked HA was almost deficient in CAFs. As reported before, suppressing the HA production of CAFs can inhibit tumor malignancy\textsuperscript{28}, so we wonder whether altering the levels of cross-linked HA could influence the pro-tumor capability of CAFs on breast cancer. As a covalent complex between HA and HCs from I-\textalpha-I, cross-linked HA is catalytically mediated by TSG6\textsuperscript{16}. Our experiment found that NFbs and CAFs with different levels of cross-linked HA were obtained through regulating TSG6 expression, whereas the quantities and MW of HA were not changed. As a result, CAFs significantly promoted the malignancy of MMTV tumor cells compared to NFbs.

**Fig. 6** The tumor growth and invasion of MMTV tumor cells in vivo. MMTV tumor cells alone or mixed with NFb\textsuperscript{Control}, NFb\textsuperscript{TSG6−}, CAF\textsuperscript{Control}, and CAF\textsuperscript{TSG6+} cells were injected into mammary fat pads of female nude mice (n = 5 each group). A Graphs showing the change of tumor volume over time. Error bars represent mean ± SEM values. Statistically significant differences were determined using \textit{t} test. *p < 0.05, **p < 0.01, ***p < 0.001. B Tumor images and statistical graph of tumor weight. Error bars represent mean ± SEM values. Statistical analysis was performed using Mann–Whitney test. *p < 0.05 (vs +NFb\textsuperscript{Control}), **p < 0.01 (vs +CAF\textsuperscript{Control}). C Ki67 expression in tumor tissues from different groups. Black nuclei indicate Ki67-positive ones. D H&E staining of muscle (M) and tumor (T) tissues.
Fig. 7 (See legend on next page.)
in vitro and in vivo. However, the breast cancer malignancy was inhibited when CAFs restored the high level of cross-linked HA, whereas NFbs with a reduced level of cross-linked HA accelerated the malignancy. Our data indicated that the conformational change of HA induced by CAFs was critical in breast cancer malignancy.

TSG6 is a secreted protein implicated in mediating immunomodulatory and beneficial activities of mesenchymal stem or stromal cells. Our study found that TSG6 levels were significantly decreased in CAFs compared to NFbs, which was consistent with the levels of cross-linked HA. Upregulation of TSG6 expression restored HA cross-linking in CAFs, verifying the inhibitory role of cross-linked HA in breast cancer malignancy. Martin et al. reported that TSG6-mediated transfer of I-α-1 HCs to HA facilitated the TGF-β-dependent differentiation of human lung fibroblasts to α-SMA-expressing myofibroblasts, suggesting that TSG6 was involved in lung fibrosis. Although α-SMA is both highly expressed in CAFs and myofibroblasts, the characteristics of CAFs in tumor microenvironment are definitely different from myofibroblasts that induce fibrosis. Therefore, the expression and function of TSG6 may vary in different fibroblasts originated from distinctive tissues and disease microenvironments. Given that TSG6 is a multifunctional molecule, we have no idea whether the regulation of TSG6 has other effects on fibroblasts besides HA cross-linking. To exclude this possibility, the typical pro-tumor cytokines TGF-β, IL-6, EGF, and HGF secreted by CAFs were assessed after the overexpression of TSG6. Our data showed that TSG6 had no significant effect on the levels of CAF-derived pro-tumor cytokines. To further verify whether the tumor-inhibiting effect is induced by cross-linked HA alone, the HA-HC complex was synthesized in vitro. As reported before, the HA-HC complex can inhibit the proliferation of macrophages and the tube formation of human umbilical vein endothelial cells. Our study found that the synthesized HA-HC complex suppressed the proliferation and invasion of breast cancer cells in a concentration-dependent manner, confirming the inhibitory role of HA cross-linking in breast cancer malignancy.

Our previous study showed that HA, especially LMW-HA, was abnormally accumulated in the serum and cancer tissues from patients with breast and colorectal cancer and associated with metastasis and prognosis. In this study, the promoting role of CAF-derived HA in breast cancer malignancy was suppressed when the conformational state was altered from non-cross-linking to cross-linking. As reported in arthritis, cross-linked HA can resist the adverse effects of HA fragmentation, which may partially explain the inhibitory effects of HA cross-linking on breast cancer malignancy. The detailed underlying mechanisms will be further explored in our future study.

In conclusion, we identified the role of HA in the malignant progression of breast cancer from a novel perspective. Our result demonstrated that HA cross-linking was deficient in breast cancer tissues, with a negative association with tumor malignancy. After restoring HA cross-linking in CAFs by regulating TSG6 expression, breast cancer malignancy was significantly suppressed in vitro and in vivo. Therefore, our study indicated that the deficiency of cross-linked HA in tumor microenvironment was CAF dependent, and restoring HA cross-linking may be a potential strategy for breast cancer treatment.

Acknowledgements
Sincere thanks for all supports.

Author contributions
F.G., C.Y., and G.Z. designed the study. G.Z., Y.H., and Y.L. performed the experiments. Y.D. and C.Y. conducted the data analysis. G.Z. and F.G. wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (82073199, 81872357, 81974446, 81974445, and 81702852), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20171924), Shanghai Pujiang Program (2019DPJ037), Shanghai “Rising Stars of Medical Talent” Youth Development Program (SHWRS2020_087), and Doctor Innovation Fund of Shanghai Jiaotong University School of Medicine (BXJ201944).

Ethics statement
This study was approved by the ethical committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. Informed consent was obtained from all participants following the Declaration of Helsinki of the World Medical Association. All protocols involving mice were approved by the Institutional Animal Care and Use Committee of Jiao Tong University Affiliated Sixth People’s Hospital.

Competing interests
The authors declare no competing interests.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-03875-6.

Received: 14 October 2020 Revised: 25 May 2021 Accepted: 25 May 2021

Published online: 07 June 2021

References

1. Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016).
2. Dang, T. T., Prechtl, A. M. & Pearson, G. W. Breast cancer subtype-specific interactions with the microenvironment dictate mechanisms of invasion. Cancer Res. 71, 6857–6866 (2011).
3. Yan, W. et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat. Cell Biol. 20, 597–609 (2018).
4. Schoppmann, S. F. et al. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res. Treat. 134, 237–244 (2012).
5. Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing intercellular signaling. J. Cell. Sci. 117, 359–367 (2004).
6. Fieber, C. et al. Hyaluronan-oligosaccharide-induced transcription of metalloproteases. J. Biol. Chem. 281, 3861–3868 (2006).
7. Mayer, K. Chemical structure of hyaluronic acid. Fed. Proc. 20, 1075–1077 (1951).
8. Merry, K. Chemical structure of hyaluronic acid. Fed. Proc. 20, 1075–1077 (1951).
9. Feyer, C. et al. Hyaluronan–oligosaccharide induced transcription of metalloproteases. J. Biol. Chem. 281, 3861–3868 (2006).
10. Lauer, M. E. et al. Modification of hyaluronan by heavy chains of inter-alpha-inhibitor in idiopathic pulmonary arterial hypertension. J. Biol. Chem. 289, 6791–6798 (2014).
11. Zhang, S., He, H., Day, A. J. & Tseng, S. C. Constitutive expression of inter-alpha-inhibitor (IαI) family proteins and tumor necrosis factor-stimulated gene-6 (TSG-6) by human amniotic membrane epithelial and stromal cells supporting formation of the heavy chain-hyaluronan (HC-HA) complex. J. Biol. Chem. 287, 12433–12444 (2012).
12. Baer, C. et al. Hyaluronan is organized into fiber-like structures along migratory pathways in the developing mouse cerebellum. Matrix Biol. 26, 348–358 (2007).
13. Baranova, N. S. et al. Inter-o-inhibitor impairs TSG-6-induced hyaluronan cross-linking. J. Biol. Chem. 288, 20942–20953 (2013).
14. Fu, L. et al. Impaired cumulus modification and female fertility in tumor necrosis factor-induced protein-6 deficient mice. Development 130, 2253–2261 (2003).
15. Majors, A. K. et al. Endoplasmic reticulum stress induces hyaluronan deposition and leukocyte adhesion. J. Biol. Chem. 278, 47223–47231 (2003).
16. Yingjung, W. et al. Molecular heterogeneity of the SHAP-hyaluronan complex. Isolation and characterization of the complex in synovial fluid from patients with rheumatoid arthritis. J. Biol. Chem. 278, 32710–32718 (2003).
17. Rugg, M. S. et al. Characterization of complexes formed between TSG-6 and inter-alpha-inhibitor that act as intermediates in the covalent transfer of heavy chains onto hyaluronan. J. Biol. Chem. 280, 25674–25686 (2005).
18. Ropponen, K. et al. Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res. 58, 342–347 (1998).
19. Posey, J. T. et al. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res. 63, 2638–2644 (2003).
20. Veleuio, C., Vaseleou, S. & Vynou, D. H. A. Guide to hyaluronan and related enzymes in breast cancer. Biological significance and diagnostic value. FEBS J. 286, 3057–3074 (2019).
21. Schwentfinger, K. L., Cowman, M. K., Telmer, P. G., Turley, E. A. & McCarthy, J. B. Hyaluronan, inflammation, and breast cancer progression. Front. Immunol. 6, 236 (2015).
22. Auvrin, P. et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 156, 529–536 (2000).
23. Kobayashi, N. et al. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res. 70, 7073–7083 (2010).
24. Brichina, A. et al. p38MAPK builds a hyaluronan cancer niche to drive lung tumorigenesis. Genes. Dev. 30, 2623–2636 (2016).
25. Zhang, Z. et al. Hyaluronan synthase 2 expressed by cancer-associated fibroblasts promotes oral cancer invasion. J. Exp. Clin. Cancer Res. 35, 181 (2016).
26. Willenberg, A., Saalbach, A., Simon, J. C. & Anderegg, U. Melanoma cells control HA synthesis in peritumoral fibroblasts via PDGF-αA and PDGF-C/C-impact on melanoma cell proliferation. J. Invest. Dermatol. 132, 385–393 (2012).
27. Edge, S. B. et al. ACC Cancer Staging Manual 7th edn (Springer, 2010).
28. Attalla, S., Tafouti, T., Bui, T. & Mulder, W. Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo. Oncogene 40, 475–491 (2021).
29. Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 15, 637–646 (2013).
30. Lauer, M. E. et al. Ineritable heavy chain transfer to hyaluronan oligosaccharides by tumor necrosis factor-stimulated gene-6. J. Biol. Chem. 288, 205–214 (2013).
31. Tan, K. T. et al. Hyaluronan, TSG-6, and inter-alpha-inhibitor in periprosthetic breasts: reduced levels of free hyaluronan and TSG-6 expression in contracted capsules. Aesthet. Surg. J. 31, 47–55 (2011).
32. Ni, K. et al. Rapid clearance of heavy chain-modified hyaluronan during resolving acute lung injury. Respir. Res. 19, 107 (2018).
33. Sivakumar, A. et al. Midgut laterality is driven by hyaluronan on the right. Dev. Cell 46, 533.e5–551.e5 (2018).
34. Nagyova, E. The biological role of hyaluronan-rich oocyte-cumulus extracellular matrix in female reproduction. Int. J. Mol. Sci. 19, 283 (2018).
35. Petrey, A. C. & de la Motte, C. A. Hyaluronan, a crucial regulator of inflammation, and breast cancer progression. Front. Cell Dev. Biol. 6, 48 (2018).
36. Day, A. J. & Milner, C. M. TSG-6: a multifunctional protein with anti-inflammatory and tissue-protective properties. Matrix Biol. 78-79, 60–83 (2019).
37. Martin, J. et al. Tumor necrosis factor-stimulated gene 6 (TSG-6)-mediated interactions with the inter-o-inhibitor heavy chain 5 facilitate tumor growth factor β1 (TGFβ1) dependent fibroblast to myofibroblast differentiation. J. Biol. Chem. 291, 13789–13801 (2016).
38. Shy, E., He, H., Sakurai, S. & Tseng, S. C. Inhibition of angiogenesis by HCHA, a complex of hyaluronan and the heavy chain of inter-alpha-inhibitor, purified from human amniotic membrane. Invest. Ophthalmol. Vis. Sci. 52, 2669–2678 (2011).
39. He, H. et al. Biochemical characterization and function of complexes formed by hyaluronan and the heavy chains of inter-alpha-inhibitor (HCHA) purified from human amniotic membrane. J. Biol. Chem. 284, 20136–20146 (2009).
40. Zhang, G. et al. Colorectal cancer-associated ~6 kDa hyaluronan serves as a novel biomarker for cancer progression and metastasis. FEBS J. 286, 3148–3163 (2019).
41. Wu, M. et al. A novel role of low molecular weight hyaluronan in breast cancer metastasis. FASEB J. 29, 1290–1298 (2015).
42. Day, A. J. & de la Motte, C. A. Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol. 26, 637–643 (2005).